Analyst Roanna Ruiz of Leerink Partners reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), retaining the price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Roanna Ruiz’s rating is based on a combination of factors that highlight the positive outlook for Xeris Pharmaceuticals. The company has provided a more precise revenue guidance for FY25, which suggests confidence in their financial projections. Additionally, the stronger than expected revenues from Recorlev in the first quarter of 2025 indicate a promising growth trajectory for this product, particularly in treating endogenous Cushing’s syndrome.
Moreover, despite facing generic competition, Keveyis revenues have shown resilience, maintaining their durability quarter over quarter. Xeris is also making strategic advancements in their clinical pipeline, notably with the development of the XP-8121 program for hypothyroidism. These factors, along with anticipated updates at the upcoming Analyst & Investor Day, contribute to the positive sentiment and Buy rating for Xeris Pharmaceuticals.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XERS in relation to earlier this year.